Results about: blood brain barrier
Our research focuses on three angles of peptide and protein chemistry: the design, synthesis and structure of bioactive molecules. From a structural perspective, we apply modern NMR techniques to study complex molecular recognition processes.
For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.
In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain.
Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.
The patients’ associations Babel Family and ASOGAF in Granada provide the funding for the initial 18 months of this challenge.
IRB Barcelona researchers publish a review article on the emerging field of drug transporters that have the capacity to reach the brain more efficiently.
IRB Barcelona is one of the few centres worldwide with a specific line of research devoted to this field, which brings together chemistry, pharmacy and biomedicine.
The article appears on the cover of the journal Chemical Society Reviews.